IRWD Ironwood Pharmaceuticals Inc

Price (delayed)

$15.07

Market cap

$2.36B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.45

Enterprise value

$2.98B

Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the ...

Highlights
IRWD's revenue is up by 8% YoY and by 2.4% QoQ
Ironwood Pharmaceuticals's gross profit has increased by 8% YoY and by 2.4% QoQ
IRWD's debt has surged by 72% year-on-year but it is down by 3.4% since the previous quarter
The company's equity has shrunk by 153% YoY and by 7% QoQ
The quick ratio has dropped by 97% year-on-year and by 4.8% since the previous quarter

Key stats

What are the main financial stats of IRWD
Market
Shares outstanding
156.53M
Market cap
$2.36B
Enterprise value
$2.98B
Valuations
Price to book (P/B)
N/A
Price to sales (P/S)
5.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.74
Earnings
Revenue
$442.74M
EBIT
-$897.12M
EBITDA
-$895.55M
Free cash flow
$183.15M
Per share
EPS
-$6.45
Free cash flow per share
$1.18
Book value per share
-$2.22
Revenue per share
$2.85
TBVPS
$3.01
Balance sheet
Total assets
$471.07M
Total liabilities
$817.37M
Debt
$715.54M
Equity
-$346.3M
Working capital
-$42.81M
Liquidity
Debt to equity
-2.07
Current ratio
0.84
Quick ratio
0.8
Net debt/EBITDA
-0.7
Margins
EBITDA margin
-202.3%
Gross margin
100%
Net margin
-226.4%
Operating margin
-213.5%
Efficiency
Return on assets
-145.6%
Return on equity
N/A
Return on invested capital
-104.8%
Return on capital employed
-460.1%
Return on sales
-202.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IRWD stock price

How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
1.41%
1 week
3.36%
1 month
11.8%
1 year
30.59%
YTD
31.73%
QTD
31.73%

Financial performance

How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$442.74M
Gross profit
$442.74M
Operating income
-$945.43M
Net income
-$1B
Gross margin
100%
Net margin
-226.4%
IRWD's revenue is up by 8% YoY and by 2.4% QoQ
Ironwood Pharmaceuticals's gross profit has increased by 8% YoY and by 2.4% QoQ
The operating income has decreased by 3.4% from the previous quarter
The net income has contracted by 2.3% from the previous quarter

Growth

What is Ironwood Pharmaceuticals's growth rate over time

Valuation

What is Ironwood Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
5.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.74
The EPS has declined by 5% since the previous quarter
The company's equity has shrunk by 153% YoY and by 7% QoQ
IRWD's P/S is 39% above its last 4 quarters average of 3.8 and 23% above its 5-year quarterly average of 4.3
IRWD's revenue is up by 8% YoY and by 2.4% QoQ

Efficiency

How efficient is Ironwood Pharmaceuticals business performance
Ironwood Pharmaceuticals's return on assets has decreased by 29% QoQ

Dividends

What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRWD.

Financial health

How did Ironwood Pharmaceuticals financials performed over time
The total assets is 42% less than the total liabilities
Ironwood Pharmaceuticals's current ratio has plunged by 97% YoY and by 7% from the previous quarter
The quick ratio has dropped by 97% year-on-year and by 4.8% since the previous quarter
The company's equity has shrunk by 153% YoY and by 7% QoQ
IRWD's debt has surged by 72% year-on-year but it is down by 3.4% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.